Table 4 |
||||||
| Multivariate Cox regression analysis (in the subpopulation of Bev-treated patients)* | ||||||
| Overall survival | Progression-free survival | |||||
| HR | 95% CI | Wald’s p | HR | 95% CI | Wald’s p | |
| Group | ||||||
| XELIRI-Bev | 1 | 1 | ||||
| FOLFIRI-Bev | 0.842 | 0.587–1.207 | 0.35 | 0.949 | 0.682–1.321 | 0.76 |
| Performance status | ||||||
| 0 | 1 | 1 | ||||
| 1–2 | 1.710 | 1.164–2.513 | 0.006 | 1.375 | 0.952–1.986 | 0.090 |
| Number of organs involved | ||||||
| 1 | 1 | 1 | ||||
| 2 | 1.580 | 1.052–2.373 | 0.027 | 1.475 | 1.019–2.135 | 0.040 |
| ≥3 | 2.598 | 1.502–4.493 | 0.001 | 2.305 | 1.337–3.973 | 0.003 |
| Osteopontin (OPN) | ||||||
| Low | 1 | 1 | ||||
| High | 1.632 | 1.116–2.387 | 0.012 | 1.467 | 1.044–2.060 | 0.027 |
*Both models remain the same whether continuous or binary variables of plasma concentrations of markers were used.
HR, hazard ratio; CI, confidence interval.
Pectasides et al. BMC Cancer 2012 12:271 doi:10.1186/1471-2407-12-271
